Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

被引：27
|
作者：
Hude, Ida [1 ,2 ]
Sasse, Stephanie [1 ]
Broeckelmann, Paul J. [1 ]
von Tresckow, Bastian [1 ]
Momotow, Jesko [1 ]
Engert, Andreas [1 ]
Borchmann, Sven [1 ]
机构：
[1] Univ Hosp Cologne, GHSG, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Ctr Zagreb, Div Haematol, Dept Internal Med, Zagreb, Croatia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 06期
关键词：
Hodgkin lymphoma; immune checkpoint inhibition; biomarkers; eosinophils; immunotherapy; BRENTUXIMAB VEDOTIN; NIVOLUMAB; BLOCKADE; FAILURE;
D O I：
10.1111/bjh.14705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：837 / 840
页数：4
相关论文
共 50 条
  • [1] BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION
    Hude, I.
    Sasse, S.
    Broeckelmann, P. J.
    von Tresckow, B.
    Momotow, J.
    Engert, A.
    Borchmann, S.
    HAEMATOLOGICA, 2017, 102 : 460 - 460
  • [2] Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors
    Borchmann, S.
    Hude, I.
    Sasse, S.
    Broeckelmann, P.
    von Tresckow, B.
    Momotow, J.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 142 - +
  • [3] Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
    Liu, Weiping
    Lin, Ningjing
    Feng, Xinqin
    Xie, Yan
    You, Chong
    Zhou, Xiaohua
    Song, Yuqin
    Zhu, Jun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [4] Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
    Weiping Liu
    Ningjing Lin
    Xinqin Feng
    Yan Xie
    Chong You
    Xiaohua Zhou
    Yuqin Song
    Jun Zhu
    Signal Transduction and Targeted Therapy, 8
  • [5] Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis
    Houk, Anna
    Gopal, Ajay K.
    Libby, Edward N.
    Shustov, Andrei R.
    Green, Damian J.
    Philip, Mary
    Orozco, Johnnie J.
    Maloney, David G.
    Press, Oliver W.
    Smith, Stephen D.
    BLOOD, 2014, 124 (21)
  • [6] PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Godfrey, James
    Siddiqi, Tanya
    Salhotra, Amandeep
    Chen, Robert
    Smith, Eileen
    Popplewell, Leslie L.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : E893 - E897
  • [7] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    HAEMATOLOGICA, 2014, 99 : 147 - 148
  • [8] Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America
    Gossen, Seisha Alana Von Glasenapp
    Martinez-Cordero, Humberto
    Villela, Luis
    Rocio Colunga-Pedraza, Perla
    Perez-Jacobo, Fernando
    Robles, Arianna
    Garces Paz, Diego Fernando
    Idrobo, Henry
    Castro, Denisse
    Rose Paredes, Sally
    Beltran, Brady E.
    Oliver, Ana Carolina
    Irigoin, Victoria
    Alejandro Ospina, Juan
    Oliday Rios, Rosa
    BLOOD, 2022, 140 : 9429 - 9430
  • [9] Lymphoma Associated Macrophages Predict Survival in Uniformly Treated Patients with Classical Hodgkin Lymphoma
    Farinha, P.
    Rodrigues, S.
    Fernandes, T.
    Monteiro, A.
    da Silva, R. Lopes
    Salvador, J.
    Gerivaz, R.
    Costa, F.
    Ferreira, G.
    Lopes, C.
    Lacerda, T.
    Ferreira, J.
    Costa, I.
    de Sousa, A. Botelho
    MODERN PATHOLOGY, 2011, 24 : 296A - 296A
  • [10] Lymphoma Associated Macrophages Predict Survival in Uniformly Treated Patients with Classical Hodgkin Lymphoma
    Farinha, P.
    Rodrigues, S.
    Fernandes, T.
    Monteiro, A.
    Lopes da Silva, R.
    Salvador, J.
    Gerivaz, R.
    Costa, F.
    Ferreira, G.
    Lopes, C.
    Lacerda, T.
    Ferreira, J.
    Costa, I.
    Botelho de Sousa, A.
    LABORATORY INVESTIGATION, 2011, 91 : 296A - 296A
12345